Brad Canino
Stock Analyst at Guggenheim
(1.61)
# 3,357
Out of 4,974 analysts
13
Total ratings
80%
Success rate
-5.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Assumes: Buy | $18 | $10.88 | +65.44% | 1 | Sep 4, 2025 | |
| RLAY Relay Therapeutics | Assumes: Buy | $15 | $4.12 | +264.08% | 1 | Sep 4, 2025 | |
| NUVL Nuvalent | Assumes: Buy | $122 | $80.89 | +50.82% | 1 | Sep 4, 2025 | |
| CCCC C4 Therapeutics | Initiates: Buy | $8 | $2.72 | +194.12% | 1 | Sep 4, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $72 | $24.06 | +199.25% | 1 | Sep 4, 2025 | |
| KURA Kura Oncology | Initiates: Neutral | n/a | $8.22 | - | 1 | Sep 4, 2025 | |
| BDTX Black Diamond Therapeutics | Initiates: Buy | $8 | $2.94 | +172.11% | 1 | Sep 4, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $40 | $25.98 | +53.96% | 1 | Sep 4, 2025 | |
| PYXS Pyxis Oncology | Initiates: Buy | $5 | $1.91 | +161.78% | 1 | Sep 4, 2025 | |
| MRSN Mersana Therapeutics | Initiates: Neutral | $450 | $6.82 | +6,498.24% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $15.05 | +265.45% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $37.88 | -20.80% | 2 | Mar 31, 2021 |
ORIC Pharmaceuticals
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $10.88
Upside: +65.44%
Relay Therapeutics
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $4.12
Upside: +264.08%
Nuvalent
Sep 4, 2025
Assumes: Buy
Price Target: $122
Current: $80.89
Upside: +50.82%
C4 Therapeutics
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.72
Upside: +194.12%
Janux Therapeutics
Sep 4, 2025
Initiates: Buy
Price Target: $72
Current: $24.06
Upside: +199.25%
Kura Oncology
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $8.22
Upside: -
Black Diamond Therapeutics
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.94
Upside: +172.11%
Summit Therapeutics
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $25.98
Upside: +53.96%
Pyxis Oncology
Sep 4, 2025
Initiates: Buy
Price Target: $5
Current: $1.91
Upside: +161.78%
Mersana Therapeutics
Mar 31, 2021
Initiates: Neutral
Price Target: $450
Current: $6.82
Upside: +6,498.24%
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $15.05
Upside: +265.45%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $37.88
Upside: -20.80%